Formestane

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Formestane

Clinical data
ATC code	L02BG02 (WHO)
Identifiers
IUPAC name (8R,9S,10R,13S,14S)-4-hydroxy-10,13-dimethyl- 2,6,7,8,9,11,12,14,15,16-decahydro-1H- cyclopenta[a]phenanthrene-3,17-dione
CAS Number	566-48-3
PubChem CID	11273
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H26O3
Molar mass	302.408 g/mol

Formestane belongs to a class of drugs known as aromatase inhibitors. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection (Lentaron).

Formestane is often used to suppress estrogen production from anabolic steroids or prohormones.

Formestane has poor oral bioavailability and as such is no longer popular as many orally available aromatase inhibitors have been developed.

It is available as a supplement for bodybuilders in transdermal formulations.

Template:Sex hormones